Meeting
2015 Genitourinary Cancers Symposium
Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)?
Authors
Christoph A. J. von Klot
Department of Urology and Urologic Oncology, Medical School Hannover, Hannover, Germany
Christoph A. J. von Klot , Alena Boeker , Thomas R. W. Herrmann , Mario W. Kramer , Markus A. Kuczyk , Axel S. Merseburger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 110)
DOI
10.1200/jco.2015.33.7_suppl.110
Abstract #
110
Poster Bd #
F2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Length and Gleason pattern at positive surgical margin after radical prostatectomy to assess risk of postoperative recurrence in localized prostate cancer.
First Author: Masashi Kato
Poster
2021 ASCO Annual Meeting
The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.
First Author: Andrew J. Armstrong
Poster
2020 Genitourinary Cancers Symposium
Advancing age and the risk of adverse pathology at radical prostatectomy in men with biopsy Gleason score 6 prostate cancer.
First Author: Daniel Kim
Poster
2019 Genitourinary Cancers Symposium
Prostate cancer (PCa) incidence and severity in 821 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry implying more than 7,000 patient-years.
First Author: Ahmad Haider